Astaxanthin - a superb natural antioxidant

Medical researchers have shown that ASTAXANTHIN may have significant pharmaceutical applications. In-vitro experiments, in-vivo pre-clinical studies and early-stage clinical trials have clearly indicated the possibility that ASTAXANTHIN itself, or in conjunction with other components, behaves like a prophylactic and curing agent against various diseases and health conditions (See Tables 2 and 3).

CONCLUSIONS AND PRODUCT FUTURE

Numerous scientific papers indicate that natural ASTAXANTHIN has great potential as a superb antioxidant with beneficial effects on various human diseases and physiological phenomena. Algatech’s advanced commercial production of natural ASTAXANTHIN from the microalga Haematococcus pluvialis supplies the market with high-quality products rich in ASTAXANTHIN, suitable for human applications. Further clinical data will strengthen the scientific basis for the role of natural ASTAXANTHIN as a unique and efficient antioxidant and for its use in human health. We expect that in a few years' time, the natural ASTAXANTHIN market will significantly increase its volume and line of applications. New specific ASTAXANTHIN-based products will be designed for the treatment of specific diseases. Some of these new products will contain other components as well (the "cocktail concept"), such as other carotenoids, antioxidants, vitamins, polyunsaturated fatty acids, minerals, and more. The natural ASTAXANTHIN market will become sophisticated and multi-product, and will include products for the food, food coloring, cosmetics and pharmaceutical industries as well.

REFERENCES

1-Boussiba S.; Vonshak A.; Cohen Z.; Richmond A. (1997)
A procedure for large scale production of Astaxanthin from Haematococcus. WO 97/28274.
2- Papas, A.M. (1999)
Antioxidant Status, Diet, Nutrition, and Health. CRC Press.
3- Palozza, P. and Krinsky, N.I. (1992)
Astaxanthin and canthaxanthin are potent antioxidants in a membrane model. Arch. Biochem. Biophys. 297: 291–295.
4- Naguib, Y.M.A. (2000)
Antioxidant activities of astaxanthin and related carotenoids. J. Agric. Food Chem. 48: 1150–1154.
5- Chew B.P. and Park J.S., (October 2003)
Dissertation in Supply Side West. Las Vegas.
6- Tso, M.O.M. and Lam, T-T. (1996)
Method of Retarding and Ameliorating Central Nervous System and Eye Damage. Assigned to U. S. Nutraceuticals. U.S. Patent #5527533.
7- Facchinetti F.; Dawson VL.; Dawson TM. (1998)
Free radicals as mediators of neuronal injury. Cell Mol Neurobiol.18(6):667-82.
8- Lorenz, R.T. and Cysewski, G.R. (2000)
Commercial potential for Haematococcus microalgae as a natural source of astaxanthin. Trends in Biotechnol. 18: 160–167.
9 - Guerin, M.; Huntley M. E.; and Olaizola M. (2003)
Haematococcus astaxanthin: applications for human health and nutrition. Trends in Biotechnol. 21: 210-216.
10- Shibata A.; Kiba Y.; Akati N.; Fukuzawa K.; Terada H. (2001)
Molecular characteristics of astaxanthin and beta-carotene in the phospholipid monolayer and their distributions in the phospholipid bilayer. Chem Phys Lipids113(1-2): 11-22.
11- Goto S.; Kogure K.; Abe K.; Kimata Y.; Kitahama K.; Yamashita E.; Terada H. (2001)
Efficient radical trapping at the surface and inside the phospholipid membrane is responsible for highly potent antiperoxidative activity of the carotenoid astaxanthin. Biochim Biophys Acta1512(2): 251-8.
12- Oshima S.; Ojima F.; Sakamoto H.; Ishiguro Y.; Terao J. (1993)
Inhibitory effect of beta-carotene and astaxanthin on photosensitized oxidation of phospholipid bilayers. J Nutr Sci Vitaminol (Tokyo) 39(6): 607-15.
13- Kurashige M.; Okimasu E.; Inoue M.; Utsumi K. (1990)
Inhibition of oxidative injury of biological membranes by astaxanthin. Physiol Chem Phys Med NMR 22(1): 27-38.
14 - Nakagawa K.; Kang SD.; Park DK.; Handelman GJ.; Miyazawa T. (1997)
Inhibition of beta-carotene and astaxanthin of NADPH-dependent microsomal phospholipid peroxidation. J Nutr Sci Vitaminol (Tokyo) 43(3): 345-55.
15– Bahner, B. (1993)
Beta –carotene use grows; natural sector in flux. Chemical Market Reporter 244:26-27.
16- Cyanotech Corporation –
Technical paper available at: http://www.cyanotech.com/pdfs/axbul60.pdf
17 - Mera Pharmaceuticals (1999)
Haematococcus pluvialis and astaxanthin safety for human consumption.
Technical Report TR.3005.001
available at http://www.astafactor.com/techreports/tr3005-001.htm
18 – La Haye - US Nutraceuticals
technical paper available at: http://www.lahaye.com/safety.html
19- Spiller GA.; Dewell A. (2003)
Safety of an Astaxanthin-Rich Haematococcus pluvialis Algal Extract: A Randomized Clinical Trial. J Med Food 6(1): 51-6.
20- Turujman, S.A. et al. (1997)
Rapid liquid chromatographic method to distinguish wild salmon from aquacultured salmon fed synthetic astaxanthin. J. AOAC Int. 80: 622–632.
21- Mercke Odeberg J.; Lignell A.; Pettersson A.; Hoglund P. (2003)
Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations. Eur J Pharm Sci 19(4): 299-304.
22- Clark RM.; Yao L.; She L.; Furr HC. (2000)
A comparison of lycopene and astaxanthin absorption from corn oil and olive oil emulsions. Lipids 35(7): 803-6.
23 - Snodderly D.M. (1995)
Evidence for protection against age related macular degeneration by caretonoids and antioxidant vitamins. Amer J. Clinical Nutrition. 63(s):1448S-1461S.
24- Ohgami K.; Shiratori K.; Kotake S.; Nishida T.; Mizuki N.; Yazawa K.; Ohno S. (2003)
Effects of astaxanthin on lipopolysaccharide-induced inflammation in vitro and in vivo. Invest Ophthalmol Vis Sci . 44(6): 2694-701.
25 - Waagbo R.; Hamre K.; Bjerkas E.; Berge R.; Wathne E.; Lie O.; Torstensen B. (2003)
Cataract formation in Atlantic salmon, Salmo salar L., smolt relative to dietary pro- and antioxidants and lipid level . J Fish Dis. 26(4): 213-29.
26- O'Connor I.; O'Brien N. (1998)
Modulation of UVA light-induced oxidative stress by beta-carotene, lutein and astaxanthin in cultured fibroblasts. J Dermatol Sci . 16(3): 226-30.
27 - Malmsten C. (1998)
Dietary supplementation with astaxanthin rich algal meal improves muscle endurance – a double blind study on male students. Unpublished study from the Karolinska Institute. Gustavberg, Sweden.
28- Lignell A. (2001)
Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseased. US patent # 6,245,818 Astacarotene AB Sweden.
29- Bennedsen, M. et al. (1999)
Treatment of H. pylori infected mice with antioxidant astaxanthin reduces gastric inflammation, bacterial load and modulates cytokine release by splenocytes. Immunol. Lett. 70: 185–189.
30- Wang X.; Willen R.; Wadstrom T. (2000)
Astaxanthin-rich algal meal and vitamin C inhibit Helicobacter pylori infection in BALB/cA mice. Antimicrob Agents Chemother 44(9): 2452-7.
31-Lignell, A. (1998)
Treatment of Dyspepsia, Patent no. WO 00/23064
32- Anderson T.; Pettersson S. (2001)
Method of inhibiting the expression of inflammatory cytokines. Patent no. WO 0172296.
33- Lorenz T. et al. (2000)
Method of retarding Ameliorating Carpel tunnel syndrome, US Patent #. 6,258,855.
34- Hughes D.A. (1999)
Effects of dietary antioxidants on the immune function of the middle aged. Proc. Nutr. Soc 58(1): 79-84.
35- Lignell A. (2001)
Use of xanthophylls, Astaxanthin e.g. for the treatment of autoimmune diseases, chronic viral and intracellular bacterial infections. Patent # WO 01/24787.
36- Lignell A. et al. (1998)
Method for the prophylactic treatment of mastitis. WO99/30701.
37- Jyonouchi, H. et al. (1995)
Effect of carotenoids on in vitro immunoglobulin production by human peripheral blood mononuclear cells: astaxanthin, a carotenoid without vitamin A activity, enhances in vitro immunoglobulin production in response to a T-dependent stimulant and antigen. Nutr. Cancer 23: 171–183.
38- Lee SJ.; Bai SK.; Lee KS.; Namkoong S.; Na HJ.; Ha KS.; Han JA.; Yim SV.; Chang K.; Kwon YG.; Lee SK.; Kim YM. (2003)
Astaxanthin inhibits nitric oxide production and inflammatory gene expression by suppressing I(kappa)B kinase-dependent NF-kappaB activation. Mol Cells Korea 16(1): 97-105.
39- Chew BP.; Wong MW.; Park JS.; Wong TS. (1999)
Dietary beta-carotene and astaxanthin but not canthaxanthin stimulate splenocyte function in mice. Anticancer Res. 19(6B): 5223-7.
40- Jyonouchi H.; Zhang L.; Tomita Y. (1993)
Studies of immunomodulating actions of carotenoids. II. Astaxanthin enhances in vitro antibody production to T-dependent antigens without facilitating polyclonal B-cell activation. Nutr Cancer 19(3): 269-80.
41- Jyonouchi H.; Hill RJ.; Tomita Y.; Good RA. (1991)
Studies of immunomodulating actions of carotenoids. I. Effects of beta-carotene and astaxanthin on murine lymphocyte functions and cell surface marker expression in in vitro culture system. Nutr Cancer 16(2): 93-105.
42- Akyon Y. (2002 )
Effect of antioxidants on the immune response of Helicobacter pylori. Clin Microbiol Infect. 8(7): 438-41.
43- Okai Y.; Higashi-Okai K. (1996)
Possible immunomodulating activities of carotenoids in in vitro cell culture experiments. Int J Immunopharmacol 18(12): 753-8.
44- Jyonouchi H.; Sun S.; Mizokami M.; Gross MD. (1996)
Effects of various carotenoids on cloned, effector-stage T-helper cell activity. Nutr Cancer 26(3): 313-24.
45- Jyonouchi H.; Sun S.; Tomita Y.; Gross MD. (1995)
Astaxanthin, a carotenoid without vitamin A activity, augments antibody responses in cultures including T-helper cell clones and suboptimal doses of antigen. J Nutr 125(10): 2483-92.
46- Jyonouchi H.; Zhang L.; Gross M.; Tomita Y. (1994)
Immunomodulating actions of carotenoids: enhancement of in vivo and in vitro antibody production to T-dependent antigens. Nutr Cancer 21(1): 47-58.
47- Murillo E. (1992)
Cholesterolemic effects of canthaxanthin & astaxanthin in rats. Arc Latinoam Nutr. 42: 409-13.
48- Iwamoto T.; Hoosoda K.; Hirano R.; Kurata H.; Matsumoto A.; Miki W.; Kamiyama M.; Itakaru H.; Yamamoto S.; Kondo K. (2001)
Inhibition of low-density lipoprotein oxidation by astaxanthin. J Atheroscler Thromb 7: 216-22
49- Zhang LX.; Cooney RV.; Bertram JS. (1991)
Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. in C3H/10T1/2 cells: relationship to their cancer chemopreventative action. Carcinogenesis 12(11): 2109-14.
50- Aoi W.; Naito Y.; Sakuma K.; Kuchide M.; Tokuda H.; Maoka T.; Toyokuni S.; Oka S.; Yasuhara M.; Yoshikawa T. (2003)
Astaxanthin limits exercise-induced skeletal and cardiac muscle damage in mice. Antioxid Redox Signal 5(1): 139-44.
51- Kang JO.; Kim SJ.; Kim H. (2001)
Effect of astaxanthin on the hepatotoxicity, lipid peroxidation and antioxidative enzymes in the liver of CCl4-treated rats. Methods Find Exp Clin Pharmacol. 23(2): 79-84.
52- Murillo E. (1992)
Hypercholesterolemic effect of canthaxanthin and astaxanthin in rats. Arch Latinoam Nutr 42(4): 409-13.
53-Rengel D.; Diez-Navajas A.; Serna-Rico A.; Veiga P.; Muga A.; Milicua JC. (2000) Exogenously incorporated ketocarotenoids in large unilamellar vesicles. Protective activity against peroxidation. Biochim Biophys Acta 1463(1): 179-87.
54- Jyonouchi H.; Sun S.; Iijima K.; Gross MD. (2000)
Antitumour activity of astaxanthin and its mode of action. Nutr cancer 36(1): 59-65.
55- Kurihara H.; Koda H.; Asami S.; Kiso Y.; Tanaka T. (2002)
Contribution of the anti oxidative property of astaxanthin to its protective effect on the promotion of cancer metastasis in mice treated with resistant stress. Life Sci. 70(21): 2509-20.
56- Tanaka T.; Makita H.; Ohnishi M.; Mori H.; Satoh K.; Hara A. (1995)
Chemoprevention of rat oral carcinogenesis by naturally occurring xanthophylls, astaxanthin and canthaxanthin. Cancer Res. 55 (18): 4059-4064.
57- Tanaka T.; Morishita Y.; Suzui M.; Kojima T.; Okumura A.; Mori H. (1994) Chemoprevention of mouse urinary bladder carcinogenesis by the naturally occurring carotenoid astaxanthin. Carcinogenesis 15(1): 15-19.
58- Tanaka T.; Kawamori T.; Ohnishi M.; Makita H.; Mori H.; Satoh K.; Ha A. (1995) Suppression of azoxymethane-induced rat colon carcinogenesis by dietary administration of naturally occurring xanthophylls astaxanthin and canthaxanthin during the postinitiation phase. Carcinogenesis 16(12): 2957-63.
59- Rousseau EJ.; Davison AJ.; Dunn B. (1992)
Protection by beta-carotene and related compounds against oxygen-mediated cytotoxicity and genotoxicity: implications for carcinogenesis and anticarcinogenesis. Free Radic Biol Med 13(4): 407-33.
60- Kozuki Y.; Miura Y.; Yagasaki K. (2000)
Inhibitory effects of carotenoids on the invasion of rat ascites hepatoma cells in culture. Cancer Lett 151(1): 111-5
61- Gradelet S.; Le Bon AM.; Berges R.; Suschetet M.; Astorg P. (1998)
Dietary carotenoids inhibit aflatoxin B1-induced liver preneoplastic foci and DNA damage in the rat: role of the modulation of aflatoxin B1 metabolism. Carcinogenesis (3): 403-11.
62- Black HS. (1998)
Radical interception by carotenoids and effects on UV carcinogenesis. Nutr Cancer 31(3): 212-7.
63 - Nishino H.; Murakosh M.; Ii T.; Takemura M.; Kuchide M.; Kanazawa M.; Mou XY.; Wada S.; Masuda M.; Ohsaka Y.; Yogosawa S.; Satomi Y.; Jinno K. (2002)
Carotenoids in cancer chemoprevention. Cancer Metastasis Rev. 21(3-4): 257-64.
64- Li Z.; Wang Y.; Mo B. (2002)
The effects of carotenoids on the proliferation of human breast cancer cell and gene expression of bcl-2. Zhonghua Yu Fang Yi Xue Za Zhi. 36(4): 254-7.
65- Chew BP.; Park JS.; Wong MW.; Wong TS. (1999)
A comparison of the anticancer activities of dietary beta-carotene, canthaxanthin and astaxanthin in mice in vivo. Anticancer Res 19(3A): 1849-53.
66- Hansen KB.; Tauson AH.; Inborr J. (2001)
Effect of supplementation with the antioxidant astaxanthin on reproduction, pre-weaning growth performance of kits and daily milk intake in mink. J Reprod Fertil Suppl. 57: 331-4.
67- Lignell et al. (1998)
Method of increasing the production and improving the quality of semen. WO99/29313.
68- Lyons NM.; O'Brien NM. (2002)
Modulatory effects of an algal extract containing astaxanthin on UVA-irradiated cells in culture. J Dermatol Sci (1): 73-84.
69- Savoure N.; Briand G.; Amory-Touz MC.; Combre A.; Maudet M.; Nicol M. (1995) Vitamin A status and metabolism of cutaneous polyamines in the hairless mouse after UV irradiation: action of beta-carotene and astaxanthin. Int J Vitam Nutr Res 65(2): 79-86.
70- Skin et al. (2001)
Effects of astaxanthin from Haematococcus pluvialis on human skin. Fragrance Journal 12: 98-103.
71- Yamahita et al, (1995)
Suppression of post-UVB hyperpigmention by topical astaxanthin from krill. Fragrance Journal 14: 180-185.
72- R. Todd Lorenz.
Method for retarding and preventing sunburn by UV light. R. Patent no. US 6,433,025 B1 Cyanotech corporation.
73- Anderson, M. (2001)
Method of Inhibiting 5-a Reductase with Astaxanthin to Prevent and Treat Benign Prostate Hyperplasia (BPH) and Prostate Cancer in Human Males. US Patent #6277417.
74- Østerlie M.; Bjerkeng B.; Liaaen-Jensen S. (1999)
On bioavailability and deposition of bent Z-isomers of astaxanthin. In: Pigments in Food Technology. Proceedings of 1st International Congress PFT (Minguez Mosquera, M. I., Galan, M. J. & Mendez, D. H., eds) pp. 157-161. International Congress on Pigments in Food Technology, Sevilla, Spain
75- Østerlie M.; Bjerkeng B.; Liaaen-Jensen S. (1999)
Blood appearance and distribution of astaxanthin E/Z isomers among plasma lipoproteins in humans administered in a single meal with astaxanthin. Abstract 2A-13. Presented at the 12th International Symposium on Carotenoids in Cairns, Queensland, Australia, July 18-23, 1999.
76 - Østerlie M.; Bjerkeng B.; Liaaen-Jensen, S. (2000)
Plasma appearance and distribution of astaxanthin E/Z and R/S isomers in plasma lipoproteins of men after single dose administration of astaxanthin. J. Nutr. Biochem. 11: 482-490.